Eurofins Scientific, a world leader in biopharmaceutical testing acquired Alphora Research Inc. to support Eurofins’ extensive drug development platform.
July 8, 2019 (Mississauga, ON) - In 2017, Eurofins Scientific (EUFI.PA), a world leader in biopharmaceutical testing acquired Alphora Research Inc. (“Alphora”) to support Eurofins’ extensive drug development platform. Starting July 2, 2019 the commercial brand for Eurofins Alphora will be Eurofins CDMO (Contract Development Manufacturing Organization) falling under the CDMO umbrella in conjunction with Eurofins Amatsigroup. Eurofins CDMO will provide an integrated, end-to-end solution for Pre-Clinical and Clinical outsourcing services of both Drug Substance/API and Drug Product manufacturing for biologics and small molecules.
- Science represents the foundation of our business and Eurofins CDMO’s agility and customized support services allow us to:
- Support clients to move rapidly through the drug development value chain
- Perform complex formulation screening and development for sterile and non-sterile manufacturing
- Accelerate process development and scale-up under GMP compliance
- Supply clinical trial materials, including packaging and logistics
- Provide regulatory compliance throughout each stage of the development cycle
About Eurofins Alphora
Eurofins Alphora provides API technology services for the scale-up of complex small molecules for pharmaceutical and biotechnology companies. The company provides flexible and sustainable solutions to support IND through to Commercial Readiness of APIs. Eurofins Alphora operates FDA and Health Canada inspected facilities including cGMP Plants, Organic Chemistry, PR&D, and Drug Product Development laboratories supported by Quality Control/Quality Assurance functions. A separate high-potency suite completes Alphora’s 74,000ft2 facilities. A 3rd cGMP plant has recently come online to add additional capacity for an active pipeline of projects.
For more information: https://www.eurofins.com/cdmo
